CNS PHARMACEUTICALS, INC. (CNSP): Price and Financial Metrics
GET POWR RATINGS... FREE!
CNSP Stock Price Chart Interactive Chart >
CNSP Price/Volume Stats
|Current price||$1.51||52-week high||$4.46|
|Prev. close||$1.48||52-week low||$1.39|
|Day high||$1.55||Avg. volume||805,697|
|50-day MA||$1.63||Dividend yield||N/A|
|200-day MA||$2.08||Market Cap||41.47M|
CNS PHARMACEUTICALS, INC. (CNSP) Company Bio
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.
Most Popular Stories View All
CNSP Latest News Stream
|Loading, please wait...|
CNSP Latest Social Stream
View Full CNSP Social Stream
Latest CNSP News From Around the Web
Below are the latest news stories about CNS Pharmaceuticals Inc that investors may wish to consider to help them evaluate CNSP as an investment opportunity.
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV ) Alkermes plc (NASDAQ: ALKS ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) Gilead Sciences, Inc. (NASDAQ: GILD ) GlaxoSmithKline plc (NYSE: GSK ) ( announced FDA approval for label expansion for its Jemperli) Novo Nordisk A/S (NYSE: NVO ) Innoviva, Inc. (NASDAQ: INVA ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI ) Omega Therapeutics, Inc. (NASDAQ: OMGA ) (IPOed July 30) Pfizer, Inc. (NYSE: PFE ) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) ResMed Inc. (NYSE: RMD ) TScan Therapeutics, Inc. (NASDAQ: TCRX ) Virpax Pharmaceutical...
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
HOUSTON , Aug. 13, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP ) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system (CNS), today reported its financial results for the quarter ended June 30, 2021 . Additionally, the Company provided a clinical update of its anti-cancer drug candidates currently in development for the treatment of primary and metastatic brain and CNS cancer. Recent Highlights Commenced patient enrollment in potentially pivotal US-based trial evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM; Granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for lead investigational dr...
CNS Pharmaceuticals (CNSP.Q), the company that licenses the drug candidate Berubicin to WPD Pharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its lead investigational drug for the treatment of patients with recurrent glioblastoma multiforme (GBM). What is Glioblastoma (GBM)? Glioblastoma (GBM) is a fatal brain  The post CNS Pharmaceuticals (CNSP.Q) Receives FDA Fast Track Designation for Berubicin appeared first on Equity.Guru .
WPD Pharmaceuticals’ Licensor Receives FDA Fast Track Designation for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme; WPD Poland Arranges Loans
VANCOUVER, British Columbia, July 12, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that CNS Pharmaceuticals Inc. (“CNS”) (NASDAQ:CNSP), the company that licenses the drug candidate Berubicin to WPD for 29 countries mainly in Europe, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for its lead investigational drug, Berubicin, for the treatm
CNSP Price Returns